In ovarian cancer, IL-6 antagonist signaling has been accepted as having a therapeutic potential through inhibition of the cytokine network.11, 24In another study,25which analyzed the level of cytokines in the peritoneal fluid of patients with ovarian cancer, higher levels of IL-6 were related to shorter disease-free survival and overall survival. Here, IL6 is linked to ovarian carcinoma.